<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Inhaled β2 adrenergic receptor (β2-AR) agonists are the mainstay of asthma therapy. The β2-AR protein is encoded by the <italic>ADRB2</italic> gene and variants within this gene can have significant consequences for modulating the response to asthma therapy. This cross-sectional study performed at the University Children’s Hospital in Belgrade, included 54 children with asthma. The subjects were genotyped for ADRB2 +46A>G (Arg16Gly, rs1042713) and +79C>G (Gln27Glu, rs 1042714) polymorphisms and the association with asthma severity and response to inhaled salbutamol was examined. In Serbian asthmatic children, allele +46A was detected with a frequency of 41.7% and allele +79G was detected with a frequency of 23.1%. Allele +46G was found to be associated with a better response to inhaled salbutamol (<italic>p</italic> &lt;0.05) and with mild form of asthma (<italic>p</italic> &lt;0.05). Polymorphism ADRB2 +46A>G may be a determinant of asthma severity and response to salbutamol in children with asthma. We did not find any association of +79C>G polymorphisms with the asthma severity and bronchodilator response to inhaled salbutamol. The results of this study can be potentially useful for personalization of asthma treatment.</p></abstract>

Inhaled β2 adrenergic receptor (β2-AR) agonists are the mainstay of asthma therapy. The β2-AR protein is encoded by the ADRB2 gene and variants within this gene can have significant consequences for modulating the response to asthma therapy. This cross-sectional study performed at the University Children’s Hospital in Belgrade, included 54 children with asthma. The subjects were genotyped for ADRB2 +46A>G (Arg16Gly, rs1042713) and +79C>G (Gln27Glu, rs 1042714) polymorphisms and the association with asthma severity and response to inhaled salbutamol was examined. In Serbian asthmatic children, allele +46A was detected with a frequency of 41.7% and allele +79G was detected with a frequency of 23.1%. Allele +46G was found to be associated with a better response to inhaled salbutamol (p <0.05) and with mild form of asthma (p <0.05). Polymorphism ADRB2 +46A>G may be a determinant of asthma severity and response to salbutamol in children with asthma. We did not find any association of +79C>G polymorphisms with the asthma severity and bronchodilator response to inhaled salbutamol. The results of this study can be potentially useful for personalization of asthma treatment.

<italic>ADRB2</italic> gene polymorphisms and salbutamol responsiveness in Serbian children with asthma

Balkan Journal of Medical Genetics

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

 gene polymorphisms and salbutamol responsiveness in Serbian children with asthma

Inhaled β2 adrenergic receptor (β2-AR) agonists are the mainstay of asthma therapy. The β2-AR protein is encoded by the ADRB2 gene and variants within this gene can have significant consequences for modulating the response to asthma therapy. This cross-sectional study performed at the University Children’s Hospital in Belgrade, included 54 children with asthma. The subjects were genotyped for ADRB2 +46A>G (Arg16Gly, rs1042713) and +79C>G (Gln27Glu, rs 1042714) polymorphisms and the association with asthma severity and response to inhaled salbutamol was examined. In Serbian asthmatic children, allele +46A was detected with a frequency of 41.7% and allele +79G was detected with a frequency of 23.1%. Allele +46G was found to be associated with a better response to inhaled salbutamol (p G may be a determinant of asthma severity and response to salbutamol in children with asthma. We did not find any association of +79C>G polymorphisms with the asthma severity and bronchodilator response to inhaled salbutamol. The results of this study can be potentially useful for personalization of asthma treatment.

Inhaled β2 adrenergic receptor (β2-AR) agonists are the mainstay of asthma therapy. The β2-AR protein is encoded by the ADRB2 gene and variants within this...

Age in years (mean±SD)	11.9±2.7
Gender (%)	M: 59.3;F: 40.7
FEV1 before salbutamol (%) (mean±SD)	87.1±11.3
FEV1 after salbutamol (%) (mean±SD)	98.8±9.1
Asthma severity: n (%) mild moderate severe	23 (42.6)14 (25.9)17 (31.5)
Atopic dermatitis: n (%)	43 (79.6)
Serum IgE (IU/mL) (mean±SD)	143.3±49.5
Blood eosinophils (%) (mean±SD)	6.3±2.1
Allele +46A>G: n (%) A G	45 (41.7)63 (58.3)
Allele +79C>G: n (%) C G	83 (76.9)25 (23.1)
Genotype +46A>G: n (%) AA GA GG	13 (24.1)19 (35.2)22 (40.7)
Genotype +79C>G: n (%) CC CG GG	34 (63.0)15 (27.8)5 (9.2)

+46A>G	AA	GA	GG	p Value
dFEV1 (%) (mean±SD)	9.4±6.2	10.4±5.8	14.4±6.1	0.044
Asthma severity: n (%)
mild	1 (4.3)	10 (43.5)	12 (52.2)
moderate	8 (57.2)	3 (21.4)	3 (21.4)	0.010
severe	4 (27.9)	6 (35.3)	7 (41.2)
Atopic dermatitis: n (%)	12 (27.9)	13 (30.2)	18 (41.9)	0.244
Eosinophils in peripheral blood (%) (mean±SD)	6.0±2.5	6.3±1.7	6.4±2.3	0.600
Serum IgE (IU/mL) (mean±SD)	152.4±47.5	128.0±53.3	148.9±49.9	0.440

ADRB2 gene polymorphisms and salbutamol responsiveness in Serbian children with asthma

Article Category: Original Article

Pubblicato online: 29 ott 2018

Pagine: 33 - 38

DOI: https://doi.org/10.2478/bjmg-2018-0007

Parole chiave
gene, Asthma, Bronchodilatator response, Polymorphism

© 2018 Jovicic N, Babic T, Dragicevic S, Nestorovic B, Nikolic A, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Demographic and clinical characteristics of patients and ADRB2 genotype distribution.

Comparison of response to salbutamol, severity of the disease and clinical characteristics between carriers of different ADRB2 genotypes.

ADRB2 gene polymorphisms and salbutamol responsiveness in Serbian children with asthma

Article Category: Original Article

Pubblicato online: 29 ott 2018

Pagine: 33 - 38

DOI: https://doi.org/10.2478/bjmg-2018-0007

Parole chiavegene, Asthma, Bronchodilatator response, Polymorphism

© 2018 Jovicic N, Babic T, Dragicevic S, Nestorovic B, Nikolic A, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Demographic and clinical characteristics of patients and ADRB2 genotype distribution.

Comparison of response to salbutamol, severity of the disease and clinical characteristics between carriers of different ADRB2 genotypes.

Parole chiave
gene, Asthma, Bronchodilatator response, Polymorphism